Page 2088 - Williams Hematology ( PDFDrive )

2062 Part XII: Hemostasis and Thrombosis Chapter 120: Hereditary Qualitative Platelet Disorders 2063

13. Castoldi E, Collins PW, Williamson PL, Bevers EM: Compound heterozygosity for 48. Bodary SC, Napier MA, McLean JW: Expression of recombinant platelet glyco-
2 novel TMEM16F mutations in a patient with Scott syndrome. Blood 117:4399–4400, protein IIbIIIa results in a functional fibrinogen-binding complex. J Biol Chem 264:
2011. 18859–18862, 1989.
14. Albers CA, Paul DS, Schulze H, et al: Compound inheritance of a low-frequency regu- 49. O’Toole TE, Loftus JC, Plow EF, et al: Efficient surface expression of platelet GPIIb-IIIa
latory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes requires both subunits. Blood 74:14–18, 1989.
TAR syndrome. Nat Genet 44:435–439, S1–S2, 2012. 50. Kolodziej MA, Vilaire G, Gonder D, et al: Study of the endoproteolytic cleavage of
15. Klopocki E, Schulze H, Strauss G, et al: Complex inheritance pattern resembling auto- platelet glycoprotein IIb using oligonucleotide-mediated mutagenesis. J Biol Chem
somal recessive inheritance involving a microdeletion in thrombocytopenia-absent 266:23499–23504, 1991.
radius syndrome. Am J Hum Genet 80:232–240, 2007. 51. Bennett JS: The molecular biology of platelet membrane proteins. Semin Hematol
16. Nurden P, Nurden AT: Congenital disorders associated with platelet dysfunctions. 27:186–204, 1990.
Thromb Haemost 99:253–263, 2008. 52. Kieffer N, Phillips DR: Platelet membrane glycoproteins: Functions in cellular interac-
17. Glanzmann E: Hereditäre hämmorhagische Thrombasthenie. Ein Beitrag zur Pathologie der tions. Annu Rev Cell Biol 6:329–357, 1990.
Blutplättchen Jahrbuch fur Kinderheilkunde und physiche Erziehung 88:113–141, 1918. 53. Seligsohn U, Coller BS, Zivelin A, et al: Immunoblot analysis of platelet GPIIb in
18. Caen JP, Castaldi PA, Leclerc JC, et al: Congenital bleeding disorders with long bleeding patients with Glanzmann thrombasthenia in Israel. Br J Haematol 72:415–423, 1989.
time and normal platelet count. I. Glanzmann’s thrombasthenia. Am J Med 41:4, 1966. 54. Mitchell WB, Li J, French DL, Coller BS: AlphaIIbbeta3 biogenesis is controlled
19. Hardisty RM, Dormandy KM, Hutton RA: Thrombasthenia: Studies on three cases. Br by engagement of alphaIIb in the calnexin cycle via the N15-linked glycan. Blood
J Haematol 10:371, 1964. 107:2713–2719, 2006.
20. Zucker MB, Pert JH, Hilgartner MW: Platelet function in a patient with thrombasthe- 55. Mitchell WB, Li J, Murcia M, et al: Mapping early conformational changes in alphaIIb
nia. Blood 28:524, 1966. and beta3 during biogenesis reveals a potential mechanism for alphaIIbbeta3 adopting
21. Weiss HJ, Kochwa S: Studies of platelet function and proteins in 3 patients with Glanzmann’s its bent conformation. Blood 109:3725–3732, 2007.
thrombasthenia. J Lab Clin Med 71:153–165, 1968. 56. Zimrin AB, Eisman R, Vilaire G, et al: Structure of platelet glycoprotein IIIa. A common
22. George JN, Caen JP, Nurden AT: Glanzmann’s thrombasthenia: The spectrum of clini- subunit for two different membrane receptors. J Clin Invest 81:1470–1475, 1988.
cal disease. Blood 75:1383–1395, 1990. 57. Cheresh DA: Human endothelial cells synthesize and express an Arg-Gly-Asp-directed
23. Nurden AT, Caen JP: An abnormal platelet glycoprotein pattern in three cases of adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc
Glanzmann’s thrombasthenia. Br J Haematol 28:253–260, 1974. Natl Acad Sci U S A 84:6471–6475, 1987.
24. Phillips DR, Jenkins CS, Luscher EF, Larrieu M: Molecular differences of exposed 58. Smith JW, Cheresh DA: The Arg-Gly-Asp binding domain of the vitronectin receptor.
surface proteins on thrombasthenic platelet plasma membranes. Nature 257:599–600, J Biol Chem 263:18726–18731, 1988.
1975. 59. Cheresh DA, Berliner SA, Vicente V, Ruggeri ZM: Recognition of distinct adhesive sites
25. Peerschke EI: The platelet fibrinogen receptor. Semin Hematol 22:241–259, 1985. on fibrinogen by related integrins on platelets and endothelial cells. Cell 58:945–953,
26. Bennett JS: The platelet-fibrinogen interaction, in Platelet Membrane Glycoproteins, 1989.
edited by JN George, AT Nurden, DR Phillips, p 193. Plenum, New York, 1985. 60. Lawler J, Hynes RO: An integrin receptor on normal and thrombasthenic platelets
27. Phillips DR, Charo IF, Parise LV, Fitzgerald LA: The platelet membrane glycoprotein which binds thrombospondin. Blood 74:2022–2027, 1989.
IIb-IIIa complex. Blood 71:831–843, 1988. 61. Yokoyama K, Zhang XP, Medved L, Takada Y: Specific binding of integrin alpha v
28. Plow EF, Ginsberg MH: Cellular adhesion: GPIIb-IIIa as a prototypic adhesion recep- beta 3 to the fibrinogen gamma and alpha E chain C-terminal domains. Biochemistry
tor. Prog Hemost Thromb 9:117–156, 1989. 38:5872–5877, 1999.
29. Poncz M, Eisman R, Heidenreich R, et al: Structure of the platelet membrane glycopro- 62. Lam SC, Plow EF, D’Souza SE, et al: Isolation and characterization of a platelet mem-
tein IIb. Homology to the alpha subunits of the vitronectin and fibronectin membrane brane protein related to the vitronectin receptor. J Biol Chem 264:3742–3749, 1989.
receptors. J Biol Chem 262:8476–8482, 1987. 63. Coller BS, Cheresh DA, Asch E, Seligsohn U: Platelet vitronectin receptor expression
30. Fitzgerald LA, Steiner B, Rall SC, et al: Protein sequence of endothelial glycoprotein differentiates Iraqi-Jewish from Arab Patients with Glanzmann thrombasthenia in
IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarity Israel. Blood 77:75–83, 1991.
to “integrin.” J Biol Chem 262:3936–3939, 1987. 64. Krissansen GW, Elliott MJ, Lucas CM, et al: Identification of a novel integrin beta sub-
31. Hynes RO: Integrins: Bidirectional, allosteric signaling machines. Cell 110:673–687, 2002. unit expressed on cultured monocytes (macrophages). J Biol Chem 265:823, 1990.
32. D’Andrea G, Colaizzo D, Vecchione G, et al: Glanzmann’s thrombasthenia: Identifica- 65. Byzova TV, Rabbani R, D’Souza SE, Plow EF: Role of integrin alpha(v)beta3 in vascular
tion of 19 new mutations in 30 patients. Thromb Haemost 87:1034–1042, 2002. biology. Thromb Haemost 80:726–734, 1998.
33. Seligsohn U, Peretz H, Newman PJ, Coller BS: Glanzmann thrombasthenia in Israel: 66. Newman PJ, Seligsohn U, Lyman S, Coller BS: The molecular genetic basis of
Clinical, biochemical and molecular genetic characterization, in Genetic Diversity Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc
Among Jews, edited by B Bonne-Tamir, A Adam, pp 275–282. Oxford University Press, Natl Acad Sci U S A 88:3160–3164, 1991.
Oxford, 1992. 67. Burk CD, Newman PJ, Lyman S, et al: A deletion in the gene for glycoprotein IIb
34. Reichert N, Seligsohn U, Ramot B: Clinical and genetic studies of Glanzmann’s throm- associated with Glanzmann’s thrombasthenia. J Clin Invest 87:270–276, 1991.
basthenia in Israel. Thromb Diath Haemorrh 34:806, 1975. 68. Poncz M, Rifat S, Coller BS, et al: Glanzmann thrombasthenia secondary to a
35. Awidi AS: Increased incidence of Glanzmann’s thrombasthenia in Jordan as compared Gly273Asp mutation adjacent to the first calcium-binding domain of platelet glycopro-
with Scandinavia. Scand J Haematol 30:218–222, 1983. tein IIb. J Clin Invest 93:172–179, 1994.
36. Khanduri U, Pulimood R, Sudarsanam A, et al: Glanzmann’s thrombasthenia. A review 69. Tadokoro S, Tomiyama Y, Honda S, et al: Missense mutations in the beta(3) subunit
and report of 42 cases from South India. Thromb Haemost 46:717–721, 1981. have a different impact on the expression and function between alpha(IIb)beta(3) and
37. Ahmed MA, Al Sohaibani MO, Al Mohaya SA, et al: Inherited bleeding disorders in the alpha(v)beta(3). Blood 99:931–938, 2002.
Eastern Province of Saudi Arabia. Acta Haematol 79:202–206, 1988. 70. Horton MA, Massey HM, Rosenberg N, et al: Upregulation of osteoclast alpha2beta1
38. Awidi AS: Rare inherited bleeding disorders secondary to coagulation factors in Jordan: integrin compensates for lack of alphavbeta3 vitronectin receptor in Iraqi-Jewish-type
A nine-year study. Acta Haematol 88:11–13, 1992. Glanzmann thrombasthenia. Br J Haematol 122:950–957, 2003.
39. Rosenberg N, Yatuv R, Orion Y, et al: Glanzmann thrombasthenia caused by an 71. French DL, Coller BS: Hematologically important mutations: Glanzmann throm-
11.2-kb deletion in the glycoprotein IIIa (beta3) is a second mutation in Iraqi Jews that basthenia. Blood Cells Mol Dis 23:39–51, 1997.
stemmed from a distinct founder. Blood 89:3654–3662, 1997. 72. Coller BS. aIIbB3: Structure and function. Thrombos and Haemostas 13(Suppl 1):S17–
40. Borhany M, Fatima H, Naz A, et al: Pattern of bleeding and response to therapy in S25, 2015.
Glanzmann thrombasthenia. Haemophilia 18:e423–e425, 2012. 73. Bajt ML, Loftus JC: Mutation of a ligand binding domain of beta 3 integrin. Integral role
41. Coller BS, Shattil SJ: The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: A technology- of oxygenated residues in alpha IIb beta 3 (GPIIb-IIIa) receptor function. J Biol Chem
driven saga of a receptor with twists, turns, and even a bend. Blood 112:3011–3025, 2008. 269:20913–20919, 1994.
42. Harrison P: Platelet α-granular fibrinogen. Platelets 3:1–10, 1992. 74. Lee JO, Rieu P, Arnaout MA, Liddington R: Crystal structure of the A domain from the
43. Coller BS, Seligsohn U, West SM, et al: Platelet fibrinogen and vitronectin in Glanz- alpha subunit of integrin CR3 (CD11b/CD18). Cell 80:631–638, 1995.
mann thrombasthenia: Evidence consistent with specific roles for glycoprotein IIb/IIIA 75. Xiong JP, Stehle T, Diefenbach B, et al: Crystal structure of the extracellular segment of
and αVβ3 integrins in platelet protein trafficking. Blood 78:2603–2610, 1991. integrin alphaVbeta3. Science 294:339–345, 2001.
44. Disdier M, Legrand C, Bouillot C, et al: Quantitation of platelet fibrinogen and throm- 76. Xiao T, Takagi J, Coller BS, et al: Structural basis for allostery in integrins and binding
bospondin in Glanzmann’s thrombasthenia by electroimmunoassay. Thromb Res to fibrinogen-mimetic therapeutics. Nature 432:59–67, 2004.
53:521–533, 1989. 77. Xiong JP, Stehle T, Zhang R, et al: Crystal structure of the extracellular segment of inte-
45. Cohen I, Gerrard JM, White JG: Ultrastructure of clots during isometric contraction. grin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 296:151–155, 2002.
J Cell Biol 91:775, 1982. 78. Zhu J, Luo BH, Xiao T, et al: Structure of a complete integrin ectodomain in a phys-
46. Gartner TK, Ogilvie ML: Peptides and monoclonal antibodies which bind to platelet iologic resting state and activation and deactivation by applied forces. Mol Cell 32:
glycoproteins IIb and/or IIIa inhibit clot retraction. Thromb Res 49:43–53, 1988. 849–861, 2008.
47. Duperray A, Troesch A, Berthier R, et al: Biosynthesis and assembly of platelet GPIIb-IIIa 79. Springer TA, Zhu J, Xiao T: Structural basis for distinctive recognition of fibrinogen
in human megakaryocytes: Evidence that assembly between pro-GPIIb and GPIIIa gammaC peptide by the platelet integrin alphaIIbbeta3. J Cell Biol 182:791–800, 2008.
is a prerequisite for expression of the complex on the cell surface. Blood 74:1603–1611, 80. Loftus JC, O’Toole TE, Plow EF, et al: A β3 integrin mutation abolishes ligand binding
1989. and alters divalent cation-dependent conformation. Science 249:915–918, 1990.

Kaushansky_chapter 120_p2039-2072.indd 2063 9/21/15 2:22 PM